Kaitlyn Arsenault - 15 Nov 2024 Form 4/A - Amendment Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Chief Financial Officer
Signature
/s/ Kaitlyn Arsenault
Issuer symbol
SKYE
Transactions as of
15 Nov 2024
Net transactions value
-$215,754
Form type
4/A - Amendment
Filing time
28 Feb 2025, 18:54:45 UTC
Date Of Original Report
19 Nov 2024
Previous filing
30 Oct 2024
Next filing
26 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SKYE Common Stock Sale $1,054 -190 -0.09% $5.55 210,548 15 Nov 2024 Direct F1
transaction SKYE Common Stock Sale $214,700 -43,026 -20% $4.99 167,522 18 Nov 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person.
F2 The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade.

Remarks:

This amendment is being filed to correct an inadvertent typographical error in the Original Form 4 in which the number of shares held by the Reporting Person following the transaction was reported as 166,342 instead of 167,522.